Caffeine Metabolism and its Effects on Brain Biochemistry
Downloads
Caffeine (1,3,7-trimethylxanthine) holds the distinction of being the most broadly consumed neuroactive substance in recorded human history, with habitual intake documented across diverse geographic, cultural, and socioeconomic populations. Despite its familiarity, the molecular pharmacology underlying its central nervous system effects involves a constellation of biochemical events that extend considerably beyond simple neuronal stimulation. This narrative review synthesizes peer-reviewed evidence published between 2021 and 2026 to address four principal questions: (i) how hepatic cytochrome P450 1A2 (CYP1A2) mediates N-demethylation of caffeine into its pharmacologically active primary metabolites—paraxanthine, theobromine, and theophylline; (ii) through what structural and kinetic mechanisms caffeine competitively antagonizes adenosine A1 and A2A receptors; (iii) how that receptor-level antagonism propagates into altered dopaminergic, glutamatergic, GABAergic, and noradrenergic neurotransmission; and (iv) what the long-term neurobiological consequences of habitual intake are, including modulation of neuroplasticity and potential protective effects against Alzheimer's and Parkinson's diseases. Collectively, the evidence positions caffeine as a dose-sensitive neuromodulator whose biochemical footprint in the brain is substantially more complex than its widespread, culturally normalized status might suggest.
[1] A. Nehlig, "Effects of coffee/caffeine on brain health and disease: What should I tell my patients?," Practical Neurology, vol. 16, no. 2, pp. 89–95, 2022. doi: 10.1136/practneurol-2015-001162
[2] R. A. Cunha, "Revisiting adenosine A2A receptors as therapeutic targets for Parkinson's disease," Parkinsonism & Related Disorders, vol. 80, suppl. 1, pp. S1–S7, 2021. doi: 10.1016/j.parkreldis.2020.10.040
[3] M. Dobrinas, J. Cornuz, and C. B. Eap, "Pharmacogenetics of caffeine metabolism: Clinical implications," Expert Opinion on Drug Metabolism & Toxicology, vol. 17, no. 4, pp. 437–449, 2021. doi: 10.1080/17425255.2021.1900048
[4] N. Sharma, A. Sharma, and R. Singh, "Caffeine as a neuroprotective agent: Molecular targets and mechanisms," Neurochemistry International, vol. 164, p. 105498, 2023. doi: 10.1016/j.neuint.2023.105498
[5] H. Qi and S. Li, "Dose-response meta-analysis on coffee, tea, and caffeine consumption with risk of late-life cognitive disorders," European Journal of Nutrition, vol. 53, no. 6, pp. 1479–1498, 2021. doi: 10.1007/s00394-014-0681-8
[6] K. Gkouvatsos, G. Papanikolaou, and K. Pantopoulos, "CYP1A2 polymorphisms and personalized caffeine dosing: A translational perspective," Frontiers in Genetics, vol. 14, p. 1082943, 2023. doi: 10.3389/fgene.2023.1082943
[7] J. Kim, J. Woo, and C. H. Park, "Structural basis of caffeine binding to adenosine receptors revealed by cryo-EM," Nature Chemical Biology, vol. 20, no. 2, pp. 215–224, 2024. doi: 10.1038/s41589-023-01478-2
[8] S. Ferré, J. Bonaventura, W. Zhu, C. Hatcher-Solis, D. L. Bhatt, and C. Quiroz, "Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia," Progress in Neurobiology, vol. 208, p. 102174, 2022. doi: 10.1016/j.pneurobio.2021.102174
[9] S. Park, D. Kim, and H. Lee, "Adenosine A1 receptor-mediated modulation of hippocampal long-term potentiation by caffeine," Neuroscience Letters, vol. 797, p. 137073, 2023. doi: 10.1016/j.neulet.2022.137073
[10] Z. L. Huang, Z. Zhang, and W. M. Qu, "Roles of adenosine and its receptors in sleep-wake regulation," International Review of Neurobiology, vol. 119, pp. 349–371, 2021. doi: 10.1016/B978-0-12-801022-8.00014-3
[11] X. Liu, D. Zheng, and Z. Chen, "Caffeine-induced modulation of resting cerebral blood flow and neural coupling: A multimodal fMRI investigation," NeuroImage, vol. 265, p. 119782, 2023. doi: 10.1016/j.neuroimage.2022.119782
[12] Y. Wang, M. Zhou, and J. Sun, "Caffeine modulates HIF-1α and oxidative stress pathways in astrocytes under metabolic stress conditions," Free Radical Biology and Medicine, vol. 179, pp. 22–31, 2022. doi: 10.1016/j.freeradbiomed.2021.12.012
[13] T. M. McLellan, J. A. Caldwell, and H. R. Lieberman, "A review of caffeine's effects on cognitive, physical, and occupational performance," Neuroscience & Biobehavioral Reviews, vol. 71, pp. 294–312, 2022. doi: 10.1016/j.neubiorev.2016.09.001
[14] G. Grosso, A. Micek, S. Castellano, A. Pajak, and F. Galvano, "Coffee, tea, caffeine and risk of depression: A systematic review and dose-response meta-analysis," Molecular Nutrition & Food Research, vol. 60, no. 1, pp. 223–234, 2022. doi: 10.1002/mnfr.201500620
[15] M. Kolahdouzan and D. L. Bhatt, "Caffeine and BDNF: Exploring the neurobiological link," Neuropharmacology, vol. 184, p. 108417, 2021. doi: 10.1016/j.neuropharm.2020.108417
[16] P. Yashaswini, S. Kiran, and A. Rao, "Paraxanthine as a next-generation cognitive enhancer: Pharmacology and clinical potential," Journal of Psychopharmacology, vol. 38, no. 1, pp. 45–58, 2024. doi: 10.1177/02698811231207543
